A new treatment involving monthly eye injections appears to help prevent blindness associated with “wet” age-related macular degeneration, according to two studies in The England Journal of Medicine.

The new treatment uses monthly eye injections of Lucentis (ranibizumab), an antibody that inhibits a protein that plays a role in the formation of new blood vessels. Wet AMD involves abnormal blood vessel formation and subsequent fluid leakage that damages the vision cells in the eye.

Wet AMD, which accounts for 10% of all AMD cases, is also known as neovascular AMD.